Evaluation of an Anti-inflammatory Diet in Autoimmune and Metabolic Diseases
NCT ID: NCT05766657
Last Updated: 2025-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
39 participants
INTERVENTIONAL
2022-12-23
2023-11-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Specifically, the primary objective of NUTRI-DIET is to validate a dietary model aimed at restoring bacterial species and/or anti-inflammatory metabolites in order to prevent extra-intestinal diseases characterized by dysbiosis, such as T1D and obesity.
The primary endpoints of the study will be to monitor the glycemic control indices, i.e., blood glucose (mean of glycemic values, percentage of time-in-range value (TIR), which will be displayed by glycemic sensor) and glycated hemoglobin for diabetic children and Body mass index (BMI) z-score according to World Health Organization (WHO) recommendations (WHO BMI-for-age boys; WHO BMI-for-age girls) for obese children.
The secondary objective of the study is to characterize the microbiota profile of the study patients and to test the algorithm under development built from the integration of diet and and gut microbiota composition data that were obtained during the previous observational study NUTRI-T1D.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Macronutrients and Gut Hormone Secretion
NCT01366794
Effect of a Dietary Intervention on Insulin Requirements in Type 1 Diabetes
NCT04944316
Effects of Standardized Meals on the Metabolic, Hormonal and Inflammatory Responses in Human
NCT02544568
The Impact of Macronutrient Composition on Glucose Dynamics in Persons With Type 1 Diabetes
NCT05268705
Elucidating the Role of Human Small Intestine Microbiota in Explaining Differences in Postprandial Glucose Responses
NCT05120661
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will last 12 months with an intervention phase (personalized diet) lasting 3 months.
The research includes an enrollment phase that may extend up to 9 months depending on the number of patients enrolled. The enrollment phase will be considered finished once a total of 80 patients (i.e., 40 pediatric patients with type 1 diabetes and 40 obese pediatric patients) are enrolled. During the patient enrollment phase, relevant clinical information (biological samples as faeces, urines and blood and questionnaires on diet habits, physical activity and stress) will be collected concurrently. Tests will be performed once enrollment is completed on samples from all patients collected at the time of enrollment (microbiota analysis on stool, metabolome analysis on stool and urine, serological gut barrier markers analysis on serum). Obese and/or diabetic children will be randomized to the intervention or control group. Randomization will be done according to age (≤12: \>12), gender and pathology (diabetes or obesity).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
Children with obesity or T1D will be randomized into this group. An individualized dietary approach will be used in this group of children.
Microbiome-targeted diet
The gut microbiota (on stool) and metabolic profile (on stool and urine) will be analyzed at time 0, and the dietary plan will contain specific directions aimed at restoring a proper metagenomic and metabolomic profile of the microbiota.
Control Group
children assigned to the control group will receive generic advice based on European dietary guidelines for obesity or follow their usual diet in the case of children with T1D.
Usual care diet
Subjects on the control group will receive general dietetic advice for Obesity or T1D
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Microbiome-targeted diet
The gut microbiota (on stool) and metabolic profile (on stool and urine) will be analyzed at time 0, and the dietary plan will contain specific directions aimed at restoring a proper metagenomic and metabolomic profile of the microbiota.
Usual care diet
Subjects on the control group will receive general dietetic advice for Obesity or T1D
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Signature of informed consent
Exclusion Criteria
2. Taking medications other than insulin, including hypolipidemic and antihypertensive drugs
3. Use of medications that could affect the results of the study, including systemic glucocorticoids and antibiotics (in the three months prior to the study)
4. Recent weight loss or weight gain (\> 3 kg), (in the 3 months preceding the study)
5. Blood transfusion in the last 3 months prior to blood sampling
6. Use of dietary supplements, including multivitamins, fish oil capsules, minerals and trace elements (three months prior to and throughout the study period)
7. Inability (physically or psychologically) to comply with the procedures required by the protocol
8. Children with specific eating disorders, which may hinder the research results
8 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IRCCS San Raffaele
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marika Falcone
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pediatric Unit
Milan, Milano, Italy
Autoimmune Pathogenesis Unit
Milan, Milan, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NUTRI-DIET
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.